Lista de obras -

A new generation of antiplatelet agents

scientific article published on July 2009

A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial

artículo científico publicado en 2013

Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial

artículo científico publicado en 2012

Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial

artículo científico publicado en 2016

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

article

An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome

artículo científico publicado en 2017

Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar

artículo científico publicado en 2015

Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial

artículo científico publicado en 2013

Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial).

artículo científico publicado en 2013

Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of randomized trials.

artículo científico publicado en 2013

Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends

artículo científico

Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

artículo científico publicado en 2017

Clinical use of novel antithrombotic agents in the management of acute coronary syndromes

artículo científico publicado en 2002

Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge

artículo científico publicado en 2006

Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis.

artículo científico publicado en 2014

Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction.

artículo científico publicado en 2012

Consensus or Controversy?: Evolution of Criteria for Myocardial Infarction After Percutaneous Coronary Intervention

artículo científico publicado en 2016

Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome

artículo científico publicado en 2017

Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

artículo científico publicado en 2016

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial

artículo científico publicado en 2014

Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial

artículo científico publicado en 2013

Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial

artículo científico publicado en 2018

Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery

artículo científico publicado en 2015

Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study.

artículo científico publicado en 2018

Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials

scientific article published on 01 February 2019

GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents?

artículo científico publicado en 2008

Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).

artículo científico publicado en 2015

Highlights from the American College of Cardiology Annual Scientific Session 2005: March 6 to 9, 2005, Orlando, Florida

artículo científico publicado en 2005

Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome

artículo científico publicado en 2018

Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes

artículo científico publicado en 2013

Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial

artículo científico publicado en 2015

Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy

artículo científico

Letter regarding article by Patti et al, "Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Re

artículo científico publicado en 2005

Long-term outcomes and causes of death after acute coronary syndrome in patients in the Bologna, Italy, area

artículo científico publicado en 2014

Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization

artículo científico

Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms

Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes

artículo científico publicado en 2015

Novel anti-platelet agents: focus on thrombin receptor antagonists

artículo científico publicado en 2013

Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites

artículo científico publicado en 2017

Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients

scientific article published on 09 May 2013

Patterns of guideline adherence and care delivery for patients with unstable angina and non-ST-segment elevation myocardial infarction (from the CRUSADE Quality Improvement Initiative).

artículo científico publicado en 2006

Pooled analysis of adverse event collection from 4 acute coronary syndrome trials

artículo científico publicado en 2016

Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI

scientific article published on 01 July 2020

Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes

artículo científico

Present and evolving role of eptifibatide in the treatment of acute coronary syndromes

artículo científico publicado en 2007

Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention.

artículo científico publicado en 2018

Promises of PAR-1 inhibition in acute coronary syndrome

artículo científico

Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome

artículo científico

Quantification of fatty tissue mass by magnetic resonance imaging in arrhythmogenic right ventricular dysplasia

artículo científico publicado en 2005

Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acu

artículo científico publicado en 2016

Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER.

artículo científico publicado en 2014

Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial

artículo científico publicado en 2012

Response to letter regarding article, “sustained ventricular tachycardia and ventricular fibrillation complicating non–ST-segment elevation acute coronary syndromes”

artículo científico publicado en 2013

Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment El

artículo científico publicado en 2013

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).

artículo científico publicado en 2016

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention

artículo científico publicado en 2010

Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function

artículo científico publicado en 2011

Scientific evidence underlying the ACC/AHA clinical practice guidelines

artículo científico publicado en 2009

Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years

artículo científico publicado en 2015

Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial

artículo científico publicado en 2018

Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome

artículo científico publicado en 2016

Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes

artículo científico

Temporal Trends in the Use of Early Cardiac Catheterization in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes (Results from CRUSADE)

artículo científico publicado en 2006

The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients

artículo científico publicado en 2006

The management of acute myocardial infarction in the cardiological intensive care units in Italy: the 'BLITZ 4 Qualità' campaign for performance measurement and quality improvement

scientific article published on June 2012

The relationship between meteorological conditions and index acute coronary events in a global clinical trial

artículo científico publicado en 2013

Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555.

scientific article published on October 2010

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

artículo científico publicado en 2011

Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?

artículo científico

Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial

artículo científico publicado en 2007

Time to coronary angiography in patients with non-ST-segment elevation acute coronary syndrome: how fast should patients go to the catheterization laboratory?

artículo científico publicado en 2008

Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE)

scientific article published on 26 March 2007

Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial

artículo científico publicado en 2017

Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials

artículo científico publicado en 2016

Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Treatment in Patients With Acute Coronary Syndrome

article

Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials

artículo científico publicado en 2011

Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial

artículo científico publicado en 2016

Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial).

artículo científico publicado en 2014

Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial

artículo científico publicado en 2016

Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).

artículo científico publicado en 2013

Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).

artículo científico publicado en 2014

Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial

artículo científico publicado en 2014

Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial.

artículo científico publicado en 2014

Lista de obras de

A new generation of antiplatelet agents

A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial

Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial

Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome

Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar

Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial

Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial).

Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of randomized trials.

Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends

Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

Clinical use of novel antithrombotic agents in the management of acute coronary syndromes

Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge

Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis.

Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction.

Consensus or Controversy?: Evolution of Criteria for Myocardial Infarction After Percutaneous Coronary Intervention

Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome

Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial

Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial

Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial

Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery

Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study.

Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials

GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents?

Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).

Highlights from the American College of Cardiology Annual Scientific Session 2005: March 6 to 9, 2005, Orlando, Florida

Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome

Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes

Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial

Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy

Letter regarding article by Patti et al, "Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Re

Long-term outcomes and causes of death after acute coronary syndrome in patients in the Bologna, Italy, area

Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization

Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms

Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes

Novel anti-platelet agents: focus on thrombin receptor antagonists

Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites

Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients

Patterns of guideline adherence and care delivery for patients with unstable angina and non-ST-segment elevation myocardial infarction (from the CRUSADE Quality Improvement Initiative).

Pooled analysis of adverse event collection from 4 acute coronary syndrome trials

Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI

Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes

Present and evolving role of eptifibatide in the treatment of acute coronary syndromes

Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention.

Promises of PAR-1 inhibition in acute coronary syndrome

Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome

Quantification of fatty tissue mass by magnetic resonance imaging in arrhythmogenic right ventricular dysplasia

Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acu

Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER.

Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial

Response to letter regarding article, “sustained ventricular tachycardia and ventricular fibrillation complicating non–ST-segment elevation acute coronary syndromes”

Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment El

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention

Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function

Scientific evidence underlying the ACC/AHA clinical practice guidelines

Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years

Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial

Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome

Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes

Temporal Trends in the Use of Early Cardiac Catheterization in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes (Results from CRUSADE)

The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients

The management of acute myocardial infarction in the cardiological intensive care units in Italy: the 'BLITZ 4 Qualità' campaign for performance measurement and quality improvement

The relationship between meteorological conditions and index acute coronary events in a global clinical trial

Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555.

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?

Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial

Time to coronary angiography in patients with non-ST-segment elevation acute coronary syndrome: how fast should patients go to the catheterization laboratory?

Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE)

Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial

Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials

Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Treatment in Patients With Acute Coronary Syndrome

Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials

Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial

Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial).

Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial